Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報

【英語タイトル】Eli Lilly and Co (LLY) - Medical Equipment - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7240)・商品コード:DATA904C7240
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:103
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes its products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co (LLY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Eli Lilly and Co, Medical Equipment, Deal Details 12
Asset Purchase 12
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 12
Eli Lilly Acquires Two Alzheimer’s Disease Imaging Agents From Siemens Medical Solutions 13
Venture Financing 14
EdiGene Raises USD15 Million in Pre-Series B Venture Financing 14
Rimidi Raises USD6.6 Million in Series A-1 Financing 15
Avedro Raises USD25 Million in Venture Financing 16
Veritas Genetics Raises USD30 Million in Series B Financing 18
Millin Enterprises Raises Funds through Series A financing 19
ACEA Biosciences Raises USD30 Million in Venture Financing 20
Microtech Medical Raises Funds through Series A Financing 21
Veritas Genetics Raises USD10 Million in Series A Financing Round 22
Companion Medical Raises USD3.15 Million in Series B Financing 23
Private Equity 24
Lilly Asia Ventures and HighLight Capital Invests USD77 Million in Sansure Biotech 24
Partnerships 25
Eli Lilly and Livongo Health Enter into Partnership 25
Eli Lilly and Co Enters into Co-Development Agreement with Rimidi Diabetes 26
DexCom Enters into Agreement with Eli Lilly 27
Insulet Enters into Co-Development Agreement with Eli Lilly 28
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 29
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 30
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 31
Corgenix Enters Into Co-Development Agreement With Eli Lilly 32
Insulet Enters Into Co-Development Agreement With Eli Lilly 33
Qiagen Enters Into Co-Development Agreement With Eli Lilly 34
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 35
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 36
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 37
Eli Lilly Enters into Licensing Agreement with Transcriptic 38
Equity Offering 39
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 39
Eli Lilly and Co – Key Competitors 41
Eli Lilly and Co – Key Employees 42
Eli Lilly and Co – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 52
Recent Developments 53
Strategy And Business Planning 53
Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 53
Financial Announcements 54
Jul 24, 2018: Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance 54
Apr 24, 2018: Lilly Reports First-Quarter 2018 Financial Results 57
Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance 62
Dec 13, 2017: Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 68
Oct 24, 2017: Lilly Reports Third-Quarter Results 2017 69
Jul 25, 2017: Lilly Reports Second-Quarter Results 74
Apr 25, 2017: Lilly Reports First-Quarter 2017 Results 78
Jan 31, 2017: Lilly Reports Fourth-Quarter And Full-Year 2016 Results 82
Corporate Communications 88
May 23, 2018: Eli Lilly and Company Announces Retirement Of Sue Mahony As President Of Lilly Oncology 88
Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology 89
Dec 11, 2017: Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology 90
Nov 13, 2017: Lilly Appoints Philip Johnson to Senior Vice President and Treasurer 91
Sep 29, 2017: Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing 92
Jun 01, 2017: Derica Rice To Retire As Lilly Chief Financial Officer 93
May 10, 2017: Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications 94
Mar 02, 2017: Lilly Announces Changes In Senior Management 95
Feb 09, 2017: Carolyn R. Bertozzi, Ph.D., Elected To Lilly Board Of Directors 96
Legal and Regulatory 97
Aug 30, 2018: Adocia announces update to second arbitration against Eli Lilly & Company 97
Government and Public Interest 98
Apr 04, 2017: Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students 98
Other Significant Developments 99
Sep 25, 2017: Geisinger And Boehringer Ingelheim Collaborate To Create A Predictive Model To Help Improve Health Outcomes For People With Type 2 Diabetes 99
Jun 21, 2017: Eli Lilly And Company Unveils Expanded Biotechnology Center In San Diego 100
May 17, 2017: Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform 101
Jan 05, 2017: Lilly To Adjust Organization And Leadership Structure To Better Align With Growth Opportunities 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
Eli Lilly and Co, Medical Equipment, Key Facts, 2017 2
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Deals By Market, 2012 to YTD 2018 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 12
Eli Lilly Acquires Two Alzheimer's Disease Imaging Agents From Siemens Medical Solutions 13
EdiGene Raises USD15 Million in Pre-Series B Venture Financing 14
Rimidi Raises USD6.6 Million in Series A-1 Financing 15
Avedro Raises USD25 Million in Venture Financing 16
Veritas Genetics Raises USD30 Million in Series B Financing 18
Millin Enterprises Raises Funds through Series A financing 19
ACEA Biosciences Raises USD30 Million in Venture Financing 20
Microtech Medical Raises Funds through Series A Financing 21
Veritas Genetics Raises USD10 Million in Series A Financing Round 22
Companion Medical Raises USD3.15 Million in Series B Financing 23
Lilly Asia Ventures and HighLight Capital Invests USD77 Million in Sansure Biotech 24
Eli Lilly and Livongo Health Enter into Partnership 25
Eli Lilly and Co Enters into Co-Development Agreement with Rimidi Diabetes 26
DexCom Enters into Agreement with Eli Lilly 27
Insulet Enters into Co-Development Agreement with Eli Lilly 28
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 29
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 30
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 31
Corgenix Enters Into Co-Development Agreement With Eli Lilly 32
Insulet Enters Into Co-Development Agreement With Eli Lilly 33
Qiagen Enters Into Co-Development Agreement With Eli Lilly 34
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 35
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 36
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 37
Eli Lilly Enters into Licensing Agreement with Transcriptic 38
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 39
Eli Lilly and Co, Key Competitors 41
Eli Lilly and Co, Key Employees 42
Eli Lilly and Co, Subsidiaries 44
Eli Lilly and Co, Joint Venture 52

List of Figures
Eli Lilly and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★調査レポート[Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報] (コード:DATA904C7240)販売に関する免責事項を必ずご確認ください。
★調査レポート[Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆